Novartis Ag (NVS) Shares Repurchased (2010 - 2025)
Novartis Ag recorded quarterly Shares Repurchased of -$2.7 billion in Q2 2025, little changed quarter-over-quarter from -$2.7 billion in Q4 2024, and down 67.95% year-over-year from -$8.5 billion in Q2 2024.
Novartis Ag's Shares Repurchased history runs 10 years deep, the most recent figure standing at -$2.7 billion for Q2 2025.
- In Q2 2025, Shares Repurchased fell 67.95% year-over-year to -$2.7 billion; the TTM figure through Jun 2025 stood at -$12.9 billion (up 17.76% YoY), while the FY2019 annual figure was -$3.0 million, up 98.8% from the prior year.
- Shares Repurchased came in at -$2.7 billion for Q2 2025 at Novartis Ag, roughly flat from -$2.7 billion in the prior quarter.
- In the past five years, Shares Repurchased ranged from a high of -$1.6 billion in Q2 2024 to a low of -$5.8 billion in Q4 2023.
- A 4-year average of -$3.4 billion and a median of -$2.7 billion in 2024 frame the typical range for Shares Repurchased.
- Across the five-year window, Shares Repurchased jumped 53.53% in 2024 and sank 67.95% in 2025, its largest moves.
- Novartis Ag's Shares Repurchased stood at -$5.3 billion in 2022, then dropped by 11.17% to -$5.8 billion in 2023, then surged by 53.53% to -$2.7 billion in 2024, then increased by 0.04% to -$2.7 billion in 2025.
- According to Business Quant data, Shares Repurchased over the past three periods registered -$2.7 billion, -$2.7 billion, and -$1.6 billion for Q2 2025, Q4 2024, and Q2 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 2.36 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 4.03 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 1.49 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 874.00 Mn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 419.00 Mn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | - |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -2.71 Bn |
| Jun 30, 2025 | -2.71 Bn |
| Dec 31, 2024 | -2.72 Bn |
| Dec 31, 2024 | -2.72 Bn |
| Jun 30, 2024 | -1.62 Bn |
| Jun 30, 2024 | -1.62 Bn |
| Dec 31, 2023 | -5.84 Bn |
| Dec 31, 2023 | -5.84 Bn |
| Jun 30, 2023 | -2.96 Bn |
| Jun 30, 2023 | -2.96 Bn |
| Dec 31, 2022 | -5.26 Bn |
| Dec 31, 2022 | -5.26 Bn |
| Jun 30, 2022 | -2.71 Bn |
| Jun 30, 2022 | -2.71 Bn |
| Dec 31, 2019 | -3.00 Mn |
| Dec 31, 2019 | -3.00 Mn |
| Jun 30, 2019 | -2.37 Bn |
| Jun 30, 2019 | -2.37 Bn |
| Mar 31, 2019 | -222.00 Mn |
| Mar 31, 2019 | -222.00 Mn |
| Dec 31, 2018 | -249.00 Mn |
| Dec 31, 2018 | -249.00 Mn |
| Jun 30, 2018 | -599.00 Mn |
| Jun 30, 2018 | -599.00 Mn |
| Mar 31, 2018 | -175.00 Mn |
| Mar 31, 2018 | -175.00 Mn |
| Dec 31, 2017 | -926.00 Mn |
| Dec 31, 2017 | -926.00 Mn |
| Jun 30, 2017 | -1.88 Bn |
| Jun 30, 2017 | -1.88 Bn |
| Jun 30, 2012 | -265.00 |
| Jun 30, 2012 | -265.00 |
| Dec 31, 2011 | -688.00 |
| Dec 31, 2011 | -688.00 |
| Dec 31, 2010 | -82.00 |
| Dec 31, 2010 | -82.00 |